3 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 1 | 1 | Unknown 1 |
Follow PTCL: new trials by email Literature Review of PTCL trials Research Report on PTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma Toripalimab, chidamide - PTCL | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 43 | 2024-04-03 | 2024-07-09 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma YY-20394 treatment - PTCL | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 90 | 2021-04-01 | 2021-01-12 |
Cyclophosphamide (1) · Doxorubicin (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Vincristine (1) · parsaclisib (1) · toripalimab (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Shanghai YingLi Pharmaceutical Co. Ltd. (1)
China (1)
Junning Cao (1)